Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Non-Current Liabilities: 2009-2023

Historic Total Non-Current Liabilities for China Pharma Holdings (CPHI) over the last 3 years, with Mar 2023 value amounting to $10.5 million.

  • China Pharma Holdings' Total Non-Current Liabilities was N/A to $10.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $10.5 million, marking a year-over-year change of. This contributed to the annual value of $11.1 million for FY2022, which is 24.71% down from last year.
  • As of Q1 2023, China Pharma Holdings' Total Non-Current Liabilities stood at $10.5 million, which was down 5.30% from $11.1 million recorded in Q4 2022.
  • China Pharma Holdings' 5-year Total Non-Current Liabilities high stood at $14.7 million for Q4 2021, and its period low was $9.6 million during Q3 2021.
  • For the 3-year period, China Pharma Holdings' Total Non-Current Liabilities averaged around $11.3 million, with its median value being $10.5 million (2023).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 42.28% in 2021, then fell by 24.71% in 2022.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Total Non-Current Liabilities stood at $10.6 million in 2019, then fell by 2.18% to $10.4 million in 2020, then spiked by 42.28% to $14.7 million in 2021, then decreased by 24.71% to $11.1 million in 2022, then reached $10.5 million in 2023.
  • Its last three reported values are $10.5 million in Q1 2023, $11.1 million for Q4 2022, and $14.7 million during Q4 2021.